Compare EAF & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EAF | SWKH |
|---|---|---|
| Founded | 1886 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | Diversified Financial Services |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.5M | 198.4M |
| IPO Year | 2018 | N/A |
| Metric | EAF | SWKH |
|---|---|---|
| Price | $9.75 | $16.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $11.75 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 252.7K | 104.8K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $13.86 |
| 52 Week High | $20.32 | $17.90 |
| Indicator | EAF | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 32.19 |
| Support Level | $7.78 | $14.69 |
| Resistance Level | $9.78 | $17.08 |
| Average True Range (ATR) | 0.69 | 0.37 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 69.85 | 12.06 |
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.